Clinical trial
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox…
NCT00316602 · Bavarian Nordic, Industry · Completed
Key facts
| NCT number | NCT00316602 |
|---|---|
| Title | A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis |
| Official title | A Multicenter, Open-label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis |
| Lead sponsor | Bavarian Nordic, Industry |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Atopic Dermatitis |
| Intervention type | Biological |
| Interventions | IMVAMUNE |
| Enrollment | 632 |
| Start date | Jul 1, 2006 |
| Primary completion | Nov 1, 2009 |
| Completion | Apr 1, 2010 |
| First posted | Apr 21, 2006 |
| Last update posted | Jan 9, 2019 |
| Countries | Mexico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: